4.8 Article

Entrainment of disrupted circadian behavior through inhibition of casein kinase 1 (CK1) enzymes

Publisher

NATL ACAD SCIENCES
DOI: 10.1073/pnas.1005101107

Keywords

circadian clock; suprachiasmatic nucleus; period protein; Tau mutation; pacemaking

Funding

  1. Biotechnology and Biological Sciences Research Council [EO232231, EO225531]
  2. Medical Research Council of the United Kingdom
  3. Biotechnology and Biological Sciences Research Council [BB/E022553/1] Funding Source: researchfish
  4. Medical Research Council [G0900414, MC_U105170643] Funding Source: researchfish
  5. BBSRC [BB/E022553/1] Funding Source: UKRI
  6. MRC [G0900414, MC_U105170643] Funding Source: UKRI

Ask authors/readers for more resources

Circadian pacemaking requires the orderly synthesis, posttranslational modification, and degradation of clock proteins. In mammals, mutations in casein kinase 1 (CK1) epsilon or delta can alter the circadian period, but the particular functions of the WT isoforms within the pacemaker remain unclear. We selectively targeted WT CK1 epsilon and CK1 delta using pharmacological inhibitors (PF-4800567 and PF-670462, respectively) alongside genetic knockout and knockdown to reveal that CK1 activity is essential to molecular pacemaking. Moreover, CK1 delta is the principal regulator of the clock period: pharmacological inhibition of CK1 delta, but not CK1 epsilon, significantly lengthened circadian rhythms in locomotor activity in vivo and molecular oscillations in the supra-chiasmatic nucleus (SCN) and peripheral tissue slices in vitro. Period lengthening mediated by CK1 delta inhibition was accompanied by nuclear retention of PER2 protein both in vitro and in vivo. Furthermore, phase mapping of the molecular clockwork in vitro showed that PF-670462 treatment lengthened the period in a phase-specific manner, selectively extending the duration of PER2-mediated transcriptional feedback. These findings suggested that CK1 delta inhibition might be effective in increasing the amplitude and synchronization of disrupted circadian oscillators. This was tested using arrhythmic SCN slices derived from Vipr2(-/-) mice, in which PF-670462 treatment transiently restored robust circadian rhythms of PER2:: Luc bioluminescence. Moreover, in mice rendered behaviorally arrhythmic by the Vipr2(-/-) mutation or by constant light, daily treatment with PF-670462 elicited robust 24-h activity cycles that persisted throughout treatment. Accordingly, selective pharmacological targeting of the endogenous circadian regulator CK1 delta offers an avenue for therapeutic modulation of perturbed circadian behavior.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available